Using Fractional Exhaled Nitric Oxide to Guide Step-Down Treatment Decisions

| March 15, 2021

Using Fractional Exhaled Nitric Oxide to Guide Step-Down Treatment Decisions

For today’s episode we will be reviewing three articles from the Sept-Oct 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging discussion with the opportunity for ongoing conversation about today’s topic!

Article links:
Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis.

Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.

Assessing the unified airway hypothesis in children via transcriptional profiling of the airway epithelium.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!
Email feedback to:

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara have nothing to disclose.

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

We’re pleased to introduce CME credit for this episode of AllergyTalk! Get credit for this episode.

ACAAI presents this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to the procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that may be referenced.